219 related articles for article (PubMed ID: 33691240)
1. The clinical significance of histone deacetylase-8 in human breast cancer.
Rahmani G; Sameri S; Abbasi N; Abdi M; Najafi R
Pathol Res Pract; 2021 Apr; 220():153396. PubMed ID: 33691240
[TBL] [Abstract][Full Text] [Related]
2. Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Pidugu VR; Yarla NS; Bishayee A; Kalle AM; Satya AK
Apoptosis; 2017 Nov; 22(11):1394-1403. PubMed ID: 28840369
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
4. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS
Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202
[TBL] [Abstract][Full Text] [Related]
5. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
6. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
7. HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.
Dasgupta T; Antony J; Braithwaite AW; Horsfield JA
J Biol Chem; 2016 Jun; 291(24):12761-12770. PubMed ID: 27072133
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Chakrabarti A; Melesina J; Kolbinger FR; Oehme I; Senger J; Witt O; Sippl W; Jung M
Future Med Chem; 2016 Sep; 8(13):1609-34. PubMed ID: 27572818
[TBL] [Abstract][Full Text] [Related]
9. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
Hsieh CL; Ma HP; Su CM; Chang YJ; Hung WY; Ho YS; Huang WJ; Lin RK
Life Sci; 2016 Apr; 151():7-14. PubMed ID: 26926079
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
12. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
13. The role of histone deacetylase 3 in breast cancer.
Rahbari R; Rasmi Y; Khadem-Ansari MH; Abdi M
Med Oncol; 2022 May; 39(5):84. PubMed ID: 35578147
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
15. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression.
Menbari MN; Rahimi K; Ahmadi A; Elyasi A; Darvishi N; Hosseini V; Mohammadi-Yeganeh S; Abdi M
Life Sci; 2019 Nov; 237():116945. PubMed ID: 31605710
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
17. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
19. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
Yan W; Liu S; Xu E; Zhang J; Zhang Y; Chen X; Chen X
Oncogene; 2013 Jan; 32(5):599-609. PubMed ID: 22391568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
